Regen BioPharma Pays Off Debt Enters Equity Financing
News related to:Regen BioPharma, Inc · 2 min read
SAN DIEGO, Nov. 05, 2026 /CourierPR/ -- Regen BioPharma, Inc., a publicly traded biotechnology company focused on immunology and immunotherapy, has made significant strides in recent months. The firm has successfully paid off two convertible notes totaling approximately $60,000. This financial maneuver was funded through the issuance of a promissory note to Coventry Enterprises LLC.
Furthermore, Regen BioPharma has entered into a common stock purchase agreement with Coventry Enterprises LLC. This agreement provides an equity financing facility, committing Coventry to purchase up to $10,000,000 worth of shares of common stock over a 36-month term. This move is expected to bolster the company's financial stability and support its ongoing research and development initiatives.
In addition to these financial updates, Regen BioPharma is also exploring strategic partnerships. The company is pursuing joint ventures that leverage artificial intelligence modeling for clinical trials. A nonbinding Letter of Intent is anticipated to be signed soon, signaling the company's commitment to innovation and collaboration.
Regen BioPharma's website has recently been compromised, leading to a temporary halt in the dissemination of news and updates through social media. The company has retained a website developer to create a new, secure platform. Meanwhile, the contact information card on the current website is now functional, allowing stakeholders to reach out directly.
The company's CEO, David R. Koos, Ph.D., is scheduled to present at the Emerging Markets conference in the near future. This presentation will provide shareholders with real-time updates on the company's progress and future plans.
Regen BioPharma, Inc. remains focused on advancing novel technologies through pre-clinical and Phase I/II clinical trials. The company is currently developing mRNA and small molecule therapies for treating cancer and autoimmune disorders. The firm's website, which has been hacked, is currently under development to ensure a secure and reliable platform for communication and information dissemination.
The company's commitment to innovation and its strategic partnerships are key to its ongoing success. The recent financial maneuvers and the planned presentation at the Emerging Markets conference underscore the company's dedication to advancing its research and development efforts. The joint ventures involving artificial intelligence modeling for clinical trials represent a significant step forward in leveraging cutting-edge technology to improve patient outcomes.
Regen BioPharma's focus on mRNA and small molecule therapies for treating cancer and autoimmune disorders highlights its commitment to addressing unmet medical needs. The company's progress in these areas is expected to have a substantial impact on the biotechnology industry and patient care.
The company's website hack and the subsequent efforts to secure a new platform reflect the challenges faced by many organizations in the digital age. However, the proactive measures taken by Regen BioPharma to address these issues demonstrate its commitment to maintaining transparency and communication with its stakeholders.
In summary, Regen BioPharma, Inc. is making significant strides in its financial and strategic initiatives, with a focus on innovation and collaboration. The company's upcoming presentation at the Emerging Markets conference and its ongoing research and development efforts are expected to drive its growth and impact in the biotechnology sector.